Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Maintenance vs Interruption in GIST
NCT05009927Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Centre Léon Bérard. Started Jan 2022; status: recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05009927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009927.